CSTL Castle Biosciences

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked among the Houston metro area’s esteemed workplaces. Castle also earned three Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and Professional Development.

“Our people-first culture is the foundation of everything we do at Castle, and it's our talented, dedicated employees who make it a great place to work," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Having worked in healthcare for more than 40 years, I can say with confidence that the people who call Castle home are truly special. They are deeply committed to our vision of transforming disease management by keeping people first, and together, we're making a real impact on the lives of patients we serve. This is a place where purpose and compassion drive innovation, and I'm honored to be part of such an exceptional team.”

Castle earned its first Top Workplaces designation in November 2021 and has maintained its strong culture of excellence while more than doubling its workforce since that time. This year alone, Castle has received 13 Top Workplaces awards, which include the following announced earlier this year:

  • Top Workplaces USA (four consecutive years)
  • Top Workplaces Healthcare Industry (three consecutive years), ranking third among other recognized companies in its size bracket in 2025
  • Top Workplaces Arizona, from AZ Central (four consecutive years)
  • Top Workplaces Greater Pittsburgh, from The Pittsburgh Post-Gazette
  • Five Top Workplaces Culture Excellence Awards in the areas of Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values

The Top Workplaces designation is based exclusively on anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures several aspects of workplace culture, including whether employees feel respected and supported, enabled to grow and empowered to execute.

The comprehensive list of 2025 Houston Chronicle Top Workplaces can be viewed . Additional information regarding the Culture Excellence Awards is available on the .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit  and connect with us on , , and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall

Source: Castle Biosciences Inc.



EN
17/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ ...

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (N...

 PRESS RELEASE

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and ...

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide pati...

 PRESS RELEASE

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 I...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch